1. Home
  2. AMTB vs REPL Comparison

AMTB vs REPL Comparison

Compare AMTB & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Amerant Bancorp Inc.

AMTB

Amerant Bancorp Inc.

HOLD

Current Price

$29.31

Market Cap

1.2B

Sector

Finance

ML Signal

HOLD

Logo Replimune Group Inc.

REPL

Replimune Group Inc.

HOLD

Current Price

$12.92

Market Cap

1.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AMTB
REPL
Founded
1979
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.4B
IPO Year
2018
2018

Fundamental Metrics

Financial Performance
Metric
AMTB
REPL
Price
$29.31
$12.92
Analyst Decision
Buy
Hold
Analyst Count
3
9
Target Price
$23.67
$5.67
AVG Volume (30 Days)
286.0K
2.6M
Earning Date
04-23-2026
05-21-2026
Dividend Yield
1.57%
N/A
EPS Growth
386.36
N/A
EPS
0.97
N/A
Revenue
N/A
N/A
Revenue This Year
$8.29
N/A
Revenue Next Year
$7.67
N/A
P/E Ratio
$29.77
N/A
Revenue Growth
N/A
N/A
52 Week Low
$15.62
$1.50
52 Week High
$30.60
$16.33

Technical Indicators

Market Signals
Indicator
AMTB
REPL
Relative Strength Index (RSI) 55.25 44.13
Support Level $28.11 $6.81
Resistance Level $30.60 $16.02
Average True Range (ATR) 0.60 0.79
MACD -0.05 -0.37
Stochastic Oscillator 61.98 0.96

Price Performance

Historical Comparison
AMTB
REPL

About AMTB Amerant Bancorp Inc.

Amerant Bancorp Inc is a bank holding company. Through its bank, it provides individuals and businesses deposit, credit, investment, wealth management, and fiduciary services, both in the United States and to select international customers. The bank also provides banking services through traditional channels, such as banking centers and ATMs, as well as via secure websites, mobile devices and telephones.

About REPL Replimune Group Inc.

Replimune Group Inc is a clinical-stage biotechnology company committed to applying its expertise in the field of oncolytic immunotherapy to transform the lives of cancer patients through novel oncolytic immunotherapies. Its proprietary oncolytic immunotherapy product candidates are designed and intended to maximally activate the immune system against cancer. Oncolytic immunotherapy is an emerging drug class. The proprietary RPx platform is based on a novel, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added that are intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. It operates in single segment of developing oncolytic immunotherapies for the treatment of cancer.

Share on Social Networks: